Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (12.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 12.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment |
Stammdaten
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Unternehmen & Branche
| Name | Aardvark Therapeutics, Inc. |
|---|---|
| Ticker | AARD |
| CIK | 0001774857 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 111,8 Mio. USD |
| Beta | 5,34 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -57,591,000 | -2.93 | 117,181,000 | 106,633,000 | |
| 2025-09-30 | 10-Q | -16,316,000 | -0.75 | 133,229,000 | 122,377,000 | |
| 2025-06-30 | 10-Q | -14,367,000 | -0.66 | 147,475,000 | 136,925,000 | |
| 2025-03-31 | 10-Q | -9,310,000 | -0.71 | 157,025,000 | 150,689,000 | |
| 2024-12-31 | 10-K | -20,588,000 | -5.15 | 77,507,000 | -54,643,000 | |
| 2024-09-30 | 10-Q | -4,182,000 | -1.05 | -46,174,000 | ||
| 2024-06-30 | 10-Q | -5,449,000 | -1.37 | -42,306,000 | ||
| 2024-03-31 | 10-Q | -2,178,000 | -0.55 | -36,911,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-11 | Lee Tien-Li | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Purchase | 7,000 | 14.49 | 101,395.00 | +180,1% | |
| 2025-12-11 | Sun Nelson | Officer, Chief Financial Officer | Open Market Purchase | 3,000 | 14.40 | 43,200.00 | +76,7% | |
| 2025-09-15 | Lee Tien-Li | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Purchase | 3,500 | 9.94 | 34,804.70 | +61,8% | |
| 2025-09-15 | Lee Tien-Li | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Purchase | 6,500 | 9.51 | 61,818.90 | +109,8% | |
| 2025-09-12 | Lee Tien-Li | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Purchase | 5,000 | 8.50 | 42,515.50 | +75,5% | |
| 2025-09-11 | Lee Tien-Li | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Purchase | 6,000 | 7.82 | 46,926.00 | +83,4% | |
| 2025-09-10 | Lee Tien-Li | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Purchase | 9,000 | 7.91 | 71,212.50 | +126,5% | |
| 2025-09-09 | Sun Nelson | Officer, Chief Financial Officer | Open Market Purchase | 6,000 | 8.07 | 48,439.80 | +86,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.